EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer

Ying Liu, Rui Tang, Yuting Cao, Nianhong Wu, Qiaoxi Qin, Yuanyuan Chen, Xi Wei, Jianli Ren, Yang Sun, Hong Zhou, Yang Zhou, Pan Li

Journal of Nanobiotechnology · 2024

DOI: 10.1186/s12951-024-02492-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nanobiotechnology, 2024. Verfasst von Ying Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Institute of Ultrasound Imaging of Chongqing Medical Univer…. Hauptthemen laut MEDLINE: Disulfiram, Triple Negative Breast Neoplasms, Matrix Metalloproteinase 2, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation Project, Chongqing Natural Science Foundation project, Sichuan Natural Science Foundation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vasculogenic mimicry (VM), when microvascular channels are formed by cancer cells independent of endothelial cells, often occurs in deep hypoxic areas of tumors and contributes to the aggressiveness and metastasis of triple-negative breast cancer (TNBC) cells. However, well-developed VM inhibitors exhibit inadequate efficacy due to their low drug utilization rate and limited deep penetration. Thus, a cost-effective VM inhibition strategy needs to be designed for TNBC treatment.

Results

Herein, we designed a low-intensity focused ultrasound (LIFU) and matrix metalloproteinase-2 (MMP-2) dual-responsive nanoplatform termed PFP@PDM-PEG for the cost-effective and efficient utilization of the drug disulfiram (DSF) as a VM inhibitor. The PFP@PDM-PEG nanodroplets effectively penetrated tumors and exhibited substantial accumulation facilitated by PEG deshielding in a LIFU-mediated and MMP-2-sensitive manner. Furthermore, upon exposure to LIFU irradiation, DSF was released controllably under ultrasound imaging guidance. This secure and controllable dual-response DSF delivery platform reduced VM formation by inhibiting COL1/pro-MMP-2 activity, thereby significantly inhibiting tumor progression and metastasis.

Conclusions

Considering the safety of the raw materials, controlled treatment process, and reliable repurposing of DSF, this dual-responsive nanoplatform represents a novel and effective VM-based therapeutic strategy for TNBC in clinical settings. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DisulfiramTriple Negative Breast NeoplasmsMatrix Metalloproteinase 2Lung NeoplasmsNanoparticlesNeovascularization, PathologicAnimalsFemaleHumansMiceCell Line, TumorMice, Inbred BALB CMice, NudeDrug RepositioningUltrasonic WavesAntineoplastic Agents

Stichwörter der Autor:innen

DisulfiramDrug penetrationLow-intensity focused ultrasoundMatrix metalloproteinase-2Vasculogenic mimicry

Substanzen

DisulfiramMatrix Metalloproteinase 2Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, Institute of Ultrasound Imaging of Chongqing Medical University, Chongqing, China.
  • Department of Ultrasound, The Third People's Hospital of Chengdu City, The Affiliated Hospital of Southwest Jiaotong University, No. 82 Qinglong Street, Chengdu, 610031, Sichuan, China.
  • Department of Pathology, The Third People's Hospital of Chengdu City, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, China.
  • Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin'…
  • Department of Ultrasound, The Third People's Hospital of Chengdu City, The Affiliated Hospital of Southwest Jiaotong University, No. 82 Qinglong Street, Chengdu, 610031, Sichuan, China. zhouyang@swjtu.edu.cn.
  • Department of Ultrasound, The Second Affiliated Hospital of Chongqing Medical University, State Key Laboratory of Ultrasound in Medicine and Engineering of Chongqing Medical University, No.76 Linjiang Road, Yuzhong Dist…

Förderung

  • National Natural Science Foundation Project
  • Chongqing Natural Science Foundation project
  • Sichuan Natural Science Foundation Project
  • Chengdu Science and Technology Bureau technology innovation research and development project
  • Science and technology project of Sichuan Provincial Health Commission
  • The Third People's Hospital of Chengdu Scientific Research Project
  • Natural Science Foundation of Sichuan Province
  • The Third People’s Hospital of Chengdu Scientific Research Project

Zitieren

APA

Liu, Y., Tang, R., Cao, Y., Wu, N., Qin, Q., Chen, Y., Wei, X., Ren, J., Sun, Y., Zhou, H., Zhou, Y., & Li, P. (2024). LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-024-02492-7

Vancouver

Liu Y, Tang R, Cao Y, Wu N, Qin Q, Chen Y, et al. LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer. Journal of Nanobiotechnology. 2024. doi:10.1186/s12951-024-02492-7

BibTeX
@article{Liu2024,
  author = {Liu, Ying and Tang, Rui and Cao, Yuting and Wu, Nianhong and Qin, Qiaoxi and Chen, Yuanyuan and Wei, Xi and Ren, Jianli and Sun, Yang and Zhou, Hong and Zhou, Yang and Li, Pan},
  title = {LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer},
  journal = {Journal of Nanobiotechnology},
  year = {2024},
  doi = {10.1186/s12951-024-02492-7}
}
Kostenlos starten →